Viemed Healthcare schedules October 20 event for Viemed Healthcare stock

Published on 10/15/2026 at 13:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viemed Healthcare stock costs EUR 8.73 on October 15, 2026. Q2 revenue was USD 78.10 million versus USD 78.00 million consensus.

Growth and investor timetable

Viemed announced its October 20, 2026 presentation on October 6, 2026.
Second-quarter revenue reached USD 78.10 million against USD 78.00 million consensus.
Viemed Healthcare stock was trading at EUR 8.73 at 1:46 p.m. CEST at Lang & Schwarz on October 15, 2026.

VMD, CA92663R1055, Illustration mit AI erstellt.

Viemed Healthcare (CA92663R1055) was trading at EUR 8.73 at Lang & Schwarz on October 15, 2026, at 1:46 p.m. CEST. FinanzNachrichten reported on October 6, 2026, that the company had scheduled a presentation for October 20, 2026, at the LD Micro Main Event.

Q2 growth broadens the platform

The scheduled presentation follows a second quarter in which Viemed expanded beyond its core ventilation business. According to Yahoo Finance, revenue reached USD 78.10 million in the second quarter of 2026, while MarketBeat reported revenue of USD 78.10 million against USD 78.00 million consensus on October 2, 2026.

The mix is changing. Ventilator rental revenue was USD 36.40 million, equipment sales reached USD 19.00 million, and service revenue was USD 6.30 million in the second quarter of 2026. That shift supports growth, but it also places more weight on operating efficiency because product and service lines carry lower adjusted EBITDA margins than rental activity.

What does the margin change mean?

Adjusted EBITDA was USD 13.70 million, or a 17.60 percent margin, in the second quarter of 2026, compared with a 22.70 percent margin in the prior-year quarter, according to Yahoo Finance. Management raised the low end of full-year 2026 revenue guidance from USD 312.00 million to USD 314.00 million, keeping the upper end at USD 320.00 million.

The company simultaneously revised full-year adjusted EBITDA guidance to USD 64.00 million to USD 68.00 million from USD 65.00 million to USD 69.00 million. Management said the revised outlook reflects a larger contribution from less capital-intensive product and service revenue, while the full-year adjusted EBITDA margin is expected to reach at least 20.00 percent.

October 20 is the next date

Viemed is scheduled to present on October 20, 2026, at 12:30 p.m. Pacific Time, according to FinanzNachrichten. The event gives investors a dated opportunity to assess whether ventilation, sleep therapy and maternal health can support the revised revenue outlook.

Stock price and operating test

For investors, the central tension is clear: Viemed delivered USD 15.90 million of operating cash flow in the second quarter of 2026, but adjusted EBITDA margin contracted to 17.60 percent. The October presentation therefore arrives with revenue momentum established and margin execution still central to the valuation discussion.

Viemed Healthcare was trading at EUR 8.73 at Lang & Schwarz on October 15, 2026, at 1:46 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Viemed Healthcare stock.